Caribou's Rachel Haurwitz speaks at TechCrunch NYC

Caribou's Rachel Haurwitz speaks at TechCrunch NYC

The Caribou CEO and co-founder spoke at TechCrunch Disrupt about the ethical and legal challenges of CRISPR technology.

Bioverativ to buy True North Therapeutics for $400M

Bioverativ to buy True North Therapeutics for $400M

True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.

Symic Bio Secures $30 Million Series B Financing

Symic Bio Secures $30 Million Series B Financing

Symic recently graduated from the QB3@953 incubator after several years' residence.

Vinod Khosla leads $24.5M Series A for Two Pore Guys

Vinod Khosla leads $24.5M Series A for Two Pore Guys

Two Pore Guys was spun out of research at UC Santa Cruz by William Dunbar and Trevor Morin. Their core technology is a handheld molecular sensor based on solid-state nanopores.

Circle Pharma expands its Series A funding

Circle Pharma expands its Series A funding

Circle was founded as a collaboration between Matt Jacobson at UCSF and Scott Lokey at UC Santa Cruz. The company is designing macrocyclic peptide therapeutics.

Celgene acquires autoimmune startup Delinia for $300M+

Celgene acquires autoimmune startup Delinia for $300M+

Celgene bought the startup for $300 million upfront to expand its inflammation and immunology pipeline with Delinia's regulatory T cell therapy.

Novartis invests in, partners with Perlara

Novartis invests in, partners with Perlara

Novartis invested and partnered with Perlara, a resident of QB3@953, to discover and develop treatments for lysosomal storage disorders using CRISPR-engineered animal models.

Meet Trace Genomics, The "23andMe" Of Soil

Meet Trace Genomics, The "23andMe" Of Soil

For $199, farmers can understand their soil better—which is key to keeping their crops healthy.

FierceBiotech Names Atreca as One of Its “Fierce 15” Biotech Companies of 2016

 FierceBiotech Names Atreca as One of Its “Fierce 15” Biotech Companies of 2016

The honor designates Atreca as one of the most promising private biotechnology companies in the industry.

Delinia Announces $35 Million Series A Financing to Advance Novel Therapeutics Targeting Regulatory T Cells for Autoimmune Diseases

Delinia Announces $35 Million Series A Financing to Advance Novel Therapeutics Targeting Regulatory T Cells for Autoimmune Diseases

The company will develop new medicines to selectively potentiate and expand regulatory T cells.